Although a beneficial effect of SGLT2 inhibitors on the decrease in estimated glomerular filtration rate (eGFR) was observed in participants with type 2 diabetes and chronic kidney disease (CKD) [8], it remains unclear whether the renoprotective effects of SGLT2 inhibitors vary depending on the degree of albuminuria. This evidence concerns the gene SLC5A2 and chronic kidney disease.